Hyperhidrosis: an update on prevalence and severity in the United States

James Doolittle, Patricia Walker, Thomas Mills, Jane Thurston, James Doolittle, Patricia Walker, Thomas Mills, Jane Thurston

Abstract

Current published estimates of the prevalence of hyperhidrosis in the United States are outdated and underestimate the true prevalence of the condition. The objectives of this study are to provide an updated estimate of the prevalence of hyperhidrosis in the US population and to further assess the severity and impact of sweating on those affected by the condition. For the purposes of obtaining prevalence, a nationally representative sample of 8160 individuals were selected using an online panel, and information as to whether or not they experience hyperhidrosis was obtained. The 393 individuals (210 female, 244 non-Hispanic white, 27 black, mean age 40.3, SE 0.64) who indicated that they have hyperhidrosis were asked further questions, including body areas impacted, severity of symptoms, age of onset, and socioemotional impact of the condition. Current results estimate the prevalence of hyperhidrosis at 4.8 %, which represents approximately 15.3 million people in the United States. Of these, 70 % report severe excessive sweating in at least one body area. In spite of this, only 51 % have discussed their excessive sweating with a healthcare professional. The main reasons are a belief that hyperhidrosis is not a medical condition and that no treatment options exist. The current study's findings with regard to age of onset and prevalence by body area generally align with the previous research. However, current findings suggest that the severity and prevalence are both higher than previously thought, indicating a need for greater awareness of the condition and its associated treatment options among medical professionals.

Keywords: Excessive sweating; Hyperhidrosis; Impact; Prevalence; Severity.

Conflict of interest statement

Current research was conducted by Burke Inc. with funding provided by Brickell Biotech, a pharmaceutical company focused on the development of treatments for dermatologic diseases and conditions. Burke Inc. assumed primary responsibility for recruiting of respondents and data analysis.

References

    1. Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology. 2013;227:10–13. doi: 10.1159/000351292.
    1. Bahar R, Liu Y, Huang Y, Phillips A, Lee TK, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH) J Am Acad Dermatol. 2016
    1. Caplin D, Austin J. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up. J Drugs Dermatol. 2014;13:449–456.
    1. Centindag I, Boley TM, Webb KN, Hazelrigg SR. Long-term results and quality-of-life measures in the management of hyperhidrosis. Thorac Surg Clin. 2008;18:217–222. doi: 10.1016/j.thorsurg.2008.01.009.
    1. Cina CS, Clase CM. The illness intrusiveness scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res. 1999;8:693–698. doi: 10.1023/A:1008968401068.
    1. Collin J, Whatling P. Treating hyperhidrosis: surgery and botulinum toxin are treatments of choice in severe cases. BMJ. 2000;320:1221–1222. doi: 10.1136/bmj.320.7244.1221.
    1. Fujimoto T, Kawahara K, Yokozeki H. Epidemiological study and considerations of primary focal hyperhidrosis in Japan: from questionnaire analysis. J Dermatol. 2013;40:886–890. doi: 10.1111/1346-8138.12258.
    1. Glaser DA, Galperin TA. Managing hyperhidrosis: emerging therapies. Dermatol Clin. 2014;32:549–553. doi: 10.1016/j.det.2014.06.003.
    1. Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg. 2007;33:76–80. doi: 10.1111/j.1524-4725.2006.32335.x.
    1. Gossot D, Galetta D, Pascal A, Debrosse D, Caliandro R, et al. Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis. Ann Thorac Surg. 2003;75:1075–1079. doi: 10.1016/S0003-4975(02)04657-X.
    1. Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. CMAJ. 2005;172:69–75. doi: 10.1503/cmaj.1040708.
    1. Hamm H. Impact of hyperhidrosis on quality of life and its assessment. Dermatol Clin. 2014;32:467–476. doi: 10.1016/j.det.2014.06.004.
    1. Hong HC, Lupin M, O’Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg. 2012;38:728–735. doi: 10.1111/j.1524-4725.2012.02375.x.
    1. Kowalski JW, Eadie N, Dagget S, Lai PY. Validity and reliability of the hyperhidrosis disease severity scale (HSDD) J Am Acad Dermatol. 2005;50(suppl):51.
    1. Leung AK, Chan PY, Choi MC. Hyperhidrosis. Int J Dermatol. 1999;8:561–567. doi: 10.1046/j.1365-4362.1999.00609.x.
    1. Liu Y, Bahar R, Kalia S, Huang RY, Phillips A, et al. Hyperhidrosis prevalence and demographical characteristics in dermatology outpatients in Shanghai and Vancouver. PLoS One. 2016;11:e0153719. doi: 10.1371/journal.pone.0153719.
    1. Naumann MK, Hamm H, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol. 2002;147:1218–1226. doi: 10.1046/j.1365-2133.2002.05059.x.
    1. Nestor MS, Park H. Safety and efficacy of micro-focused ultrasound plus visualization for the treatment of axillary hyperhidrosis. J Clin Aesthet Dermatol. 2014;7:14–21.
    1. Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg. 2002;35:382–386. doi: 10.1067/mva.2002.119507.
    1. Shayesteh A, Janlert U, Brulin C, Boman J, Nylander E. Prevalence and characteristics of hyperhidrosis in Sweden: a cross-sectional study in the general population. Dermatology. 2016
    1. Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, et al. A comprehensive approach to the recognition and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33:908–923.
    1. Stolman LP. Treatment of hyperhidrosis. Dermatol Clin. 1998;16:863–867. doi: 10.1016/S0733-8635(05)70062-0.
    1. Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004;51:241–248. doi: 10.1016/j.jaad.2003.12.040.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren